-
2025-522033-64-00
1
2026-02-26
Myelofibrosis
-
2025-522273-10-00
3
2026-02-24
Rheumatoid Arthritis
-
2024-520098-12-00
4
2026-02-16
Cutaneous Lupus Erythematosus
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-521919-39-00
3
2026-02-10
Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-518936-36-00
6
2026-01-23
Active smokers
-
2024-512486-14-00
5
2026-01-22
Short Bowel Syndrome
-
2025-521352-38-00
5
2026-01-16
Hereditary Angioedema
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2024-511508-18-00
9
2026-01-05
Chronic graft versus host disease.
-
2025-521562-95-00
5
2025-12-30
Previously Untreated Advanced (Unresectable or Metastatic) Melanoma
-
2023-508995-12-01
4
2025-12-24
Recurrent or metastatic non-small cell lung cancer (NSCLC)
-
2024-518588-36-00
5
2025-12-24
Refractory or Relapsed Multiple Myeloma
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2022-503140-41-00
5
2025-12-19
Melanoma
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-521672-60-00
7
2025-12-19
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
-
2024-514327-42-00
4
2025-12-18
Advanced neuroendocrine carcinomas (NECs) of the digestive system or u